Offering HIV prevention pills alongside opioid replacement treatment at pharmacies
Tests whether pharmacies can offer HIV prevention pills with opioid replacement treatment.
Plain-language title generated from the registry record
Registry title: HIV Prevention With PrEP Among People on Opioid Replacement Therapy
Key facts
- Where
- Calgary, Regina, and Saskatoon, CanadaSee the 6 sites
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people without HIV who are on opioid agonist therapy and may be exposed to HIV. It tests taking oral PrEP together with OAT at pharmacy-based programs.
- Age
- 16 years and older
- Sex
- All sexes can join.
- Earlier treatment
- Must be regularly in their OAT program, at least 3 days a week for the past 2 weeks. Must not have taken PrEP in the last 24 hours.
- Biomarker or test result
- HIV negative.
Main reasons for not taking part
- Creatine clearance below 30 mL/min
- A medical condition or medication that cannot be combined with Emtricitabine/Tenofovir Alafenamide (F/TAF) or Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
- Took PrEP within the last 24 hours at screening or enrollment
- A clinician finds HIV Post-Exposure Prophylaxis appropriate at screening or enrollment
Read by machine on 9 November 2026.
Where in Canada
- Sheldon M. Chumir Health CentreCalgary, CanadaNot yet recruiting
- Queen City Wellness PharmacyRegina, CanadaNot yet recruiting
- Mayfair Drugs PharmacySaskatoon, CanadaTaking people
- Meadowgreen PharmacySaskatoon, CanadaTaking people
- Pharmasave Riversdale PharmacySaskatoon, CanadaTaking people
- The Medicine Shoppe PharmacySaskatoon, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cara Spence
- Trial code
- NCT07160075
- Record updated
- 7 October 2025
- Original description
The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest / acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention.Read full original descriptionShow less
Improving Access to HIV Pre-exposure Prophylaxis: Implementation and Evaluation of Innovative HIV Prevention Services Among Persons on Opioid Replacement Therapy in Western Canada: Prospective, Implementation Study
The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest / acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention.
Inclusion: HIV negative; Ongoing behaviors with potential HIV exposure as assessed by a clinician; Regularly engaged with their respective OAT program at least 3 days a week for the past 2 weeks; Report willingness to return for follow-up visits.
Exclusion: Deemed appropriate by a clinician for HIV Post-Exposure Prophylaxis at the time of screening or enrollment; Creatine clearance <30 mL/min or any medical condition or medication known to be contraindicated with the use of Emtricitabine/Tenofovir Alafenamide (F/TAF) or Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF); Taken PrEP within the last 24 hours at the time of screening or enrollment.